In experimental and clinical studies it has been found that antidepressants possess antinociceptive and analgesic properties and are therefore used in the combined therapy of chronic pain. 1 The serotoninselective reuptake inhibitors (SSRIs) were fi rst introduced as a new class of antidepressants at the end of 1980s and due to their favorable side-effect profi le have since become fi rst-line therapy of depressive disorders. 2 Most SSRIs have been found to also possess secondary binding properties -dopamine reuptake inhibition, noradrenaline reuptake inhibition, muscarinic cholinergic antagonism, etc. 3 Only citalopram and its S(+)-enantiomer escitalopram are considered highly-selective SSRIs. 4 The mechanisms responsible for the antinociceptive and analgesic effects of antidepressants are not entirely clear but it has been hypothesized that their effects are due to, at least partially, their inhibition of reuptake of serotonin. 5 The "not so selective" SSRIs (e.g. fl uvoxamine, fl uoxetine) induce dose-dependent antinociceptive effects. 2, 6 In a clinical study conducted by Jaracz et al. in 2015, escitalopram shows pain-relieving action 7 , but in the available scientifi c literature there is insuffi cient experimental data on its analgesic effect and the mechanisms by which it is mediated.
AIM
The aim of this study is to evaluate the antinociceptive properties of escitalopram after a single administration using animal pain models. The animals were maintained on a light-dark cycle of 12:12 h in a temperature-controlled environment with food and water available ad libitum.
ANTINOCICEPTION ASSESSMENT
Hot plate test -individual rats were placed on a hot plate (Ugo Basile, Italy) maintained at a constant temperature of 55±0.5°C. The time between the placement of the animal on the plate surface until it licked its back paw, jumped out or attempted vocalization was measured. A 30 sec cut-off time was set in order to prevent tissue damage.
Plantar test (Hargreaves method) -the animals were placed in individual compartments. After an acclimation period an infrared source (Ugo Basile, Italy) was positioned under the glass fl oor directly beneath the hind paw of the animals and paw withdrawal latency was measured. In each compartment the animal was unrestrained.
Paw pressure test (Randall-Selitto method) -an analgesy-meter device (Ugo Basile, Italy), which exerts a steadily increasing force, was used. This force was applied to the rat's hind paw and the pressure at which the animal withdraws the tested paw was measured.
The tests were performed at 1, 2, and 3 hours after administration of the test substances. Criterion for analgesic action was lengthening of the reaction time, compared to the animals treated with saline.
Formalin test -200 μl of 0.2% formalin was injected intradermally in one of the hind paws one hour after the administration of the tested substances. The time in seconds for licking the injected paw was counted during the fi rst 10 minutes and at 20 and 30 minutes after injection. Criterion for analgesic effect was decreased paw licking time in comparison to the control group.
STATISTICAL ANALYSIS Statistical evaluation of the results was performed with IBM SPSS 20.0. Kolmogorov-Smirnov test was used to determine the distribution. For each indicator we determined the arithmetic mean and standard error of the mean (± SEM). Comparison of the results between groups was done using the independent sample t test. A p value < 0.05 was considered statistically signifi cant.
RESULTS
The reference analgesic metamizole showed a significant analgesic effect (р<0.05) in all tests excluding the fi rst phase of the formalin test. In the plantar test escitalopram in a dose of 5 mg/ kg b.w. signifi cantly increased paw withdrawal time at 1 hour (p<0.05), 2 hours (p<0.05), and 3 hours (p<0.05) compared to the control group. A dose of 10 mg/kg b.w. lengthened the reaction time at 1 hour (p<0.05), 2 hours (p<0.05), and 3 hours (p<0.05) in comparison to the control animals. Escitalopram in a dose of 20 mg/kg b.w. increased withdrawal latency at 1 hour (p<0.05), 2 hours (p<0.05) and 3 hours (p<0.05) compared to the animals treated with saline ( Fig. 1) .
In the hot plate test, escitalopram in a dose of 5 mg/kg b.w. signifi cantly lengthened the duration of the stay on the plate at 1 hour (р<0.05) compared to the control animals. 10 mg/kg b.w. of escitalopram increased the reaction time at one hour (р<0.05) and 3 hours (р<0.05) compared to the saline treated animals. In a dose of 20 mg/kg b.w. escitalopram the nociceptive response latency at 1 hour (р<0.05) and 3 hours (р<0.05) in comparison to the control group (Fig. 2) .
At a dose of 5 mg/kg b.w. escitalopram significantly increased the latency in paw pressure test at 2 hours (р<0.05, compared to the control group. Using a dose of 10 mg/kg b.w. did not result in lengthening the time for paw withdrawal. At a dose of 20 mg/kg b.w. escitalopram increased reaction time at 2 hours (р<0.05), compared to the saline treated group (Fig. 3) .
Using 5 mg doses of escitalopram signifi cantly decreased the fi rst phase hind paw licking time (p<0.05) in the formalin test compared to the control group. Escitalopram in a dose of 10 mg/kg b.w. reduced paw licking time in the second phase of the test (p<0.05) in comparison to control group. w. on the nociceptive threshold in the hot plate test after a single administration. * р < 0.05 compared to the control group at 1 hour; ** р < 0.05 compared to the control group at 2 hours; *** р < 0.05 compared to the control group at 3 hours. At a dose of 20 mg/kg b.w. escitalopram decreased the second phase hind paw licking time (p<0.05) in the formalin test in comparison with the control animals (Fig. 4.) .
DISCUSSION
The results in our study indicate that in experimental conditions the SSRI escitalopram has analgesic action against thermal, mechanical and chemical stimuli. This effect is registered after a single administration of the drug.
In the hot plate test the smallest dose of escitalopram showed significant antinociceptive effect only at 1 hour. The higher doses of the drug showed analgesic action at 1 hour and 3 hours. The parameters we observed in this test (paw licking, jumping out, and vocalization) are supraspinally integrated responses 8 which suggests the participation of supraspinal pathways in the escitalopram-induced antinociception. This is supported by reports in the literature demonstrating that supraspinal monoaminergic pathways are involved in the subjective experience and behavioral expression of pain. 5 The Hargreaves test is developed to deliver a more localized heat on unrestrained animals and offers the advantage of minimizing the role of subjective factors. In this test escitalopram in all used doses had a signifi cant analgesic effect. The behavioral refl ex response in this test is mediated by supraspinal structures 9 , hence we can assume that supraspinal pathways are involved in the analgesia induced by escitalopram.
In the paw pressure test escitalopram (5 and 20 mg/kg b.w.) signifi cantly prolonged reaction time at 2 hours. Paw withdrawal due to increased mechanical pressure is a spinal refl ex, although it is sometimes accompanied by a struggle or a vocal reaction, which are behaviors mediated by supraspinal structures. 9 Intraplantar administration of formalin leads to biphasic pain response. The initial phase covers the fi rst ten minutes and results from direct activation of nociceptors. The second phase occurs after a ten minute quiescent period and is attributed to the release of local endogenous mediators, leading to peripheral infl ammatory processes and subsequent sensitization of nociceptive spinal neurons. 10 Serotonin is a key modulator of nociceptive transmission primarily at spinal cord level, where 5НТ-2 and 5НТ-3 receptors mediate its inhibitory effect on pain. 11, 12 In a formalin test of normal and genetically modifi ed mice lacking central serotonergic neurons (line Lmx1b f/f/p ) no signifi cant difference was found in the fi rst phase of the test and enhancement of behavioral responses in Lmx1b f/f/p line in the second phase. 13 In our study 10 and 20 mg/kg b.w. of escitalopram showed signifi cant antinociceptive effect in the second phase of the formalin test. We can speculate that spinal pathways are also implicated in the mode of antinociceptive action of escitalopram. Further investigations with serotonin receptor antagonists are necessary to establish the role of specifi c 5-HT receptor subtypes in the ant inociceptive action of escitalopram.
CONCLUSION
Escitalopram induces antinociceptive effect after a single administration in rats. This effect is not dosedependent or time-dependent. The most sensitive model for studying the analgesic effect of escitalopram is the plantar test in which all doses used in the experiment show signifi cant analgesic action.
